The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial

JB Weidhaas, J Harris, D Schaue, AM Chen… - JAMA …, 2017 - jamanetwork.com
Importance There is a significant need to find biomarkers of response to radiotherapy and
cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and …
被引用次数：64 相关文章

The KRAS-variant and cetuximab response in head and neck squamous cell cancer a secondary analysis of a randomized clinical trial

JB Weidhaas, J Harris, D Schaue, AM Chen… - JAMA …, 2017 - pure.johnshopkins.edu
IMPORTANCE: There is a significant need to find biomarkers of response to radiotherapy
and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and …

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

JB Weidhaas, J Harris, D Schaue, AM Chen… - JAMA …, 2017 - europepmc.org
Objectives To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-
variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker …
[PDF] academia.edu

[PDF][PDF] The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer A Secondary Analysis of a Randomized Clinical Trial

JB Weidhaas, J Harris, D Schaue, AM Chen, R Chin… - JAMA, 2017 - academia.edu
OBJECTIVES To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)–
variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker …
[HTML] escholarship.org

[HTML][HTML] The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial

JB Weidhaas, J Harris, D Schaue, AM Chen… - JAMA …, 2017 - escholarship.org
ImportanceThere is a significant need to find biomarkers of response to radiotherapy and
cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and …

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial

JB Weidhaas, J Harris, D Schaue… - JAMA …, 2017 - pubmed.ncbi.nlm.nih.gov
Importance There is a significant need to find biomarkers of response to radiotherapy and
cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and …
[HTML] nih.gov

[HTML][HTML] The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial

JB Weidhaas, J Harris, D Schaue, AM Chen… - JAMA …, 2017 - ncbi.nlm.nih.gov
Objectives To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)–
variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker …

The KRAS-variant and cetuximab response in head and neck squamous cell cancer a secondary analysis of a randomized clinical trial

JB Weidhaas, J Harris, D Schaue… - JAMA …, 2017 - mdanderson.elsevierpure.com
IMPORTANCE: There is a significant need to find biomarkers of response to radiotherapy
and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and …

[引用][C] The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer

JB Weidhaas, J Harris, D Schaue, AM Chen, R Chin… - JAMA Oncology, 2017 - cir.nii.ac.jp
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer A Secondary Analysis of a Randomized Clinical Trial

JB Weidhaas, J Harris, D Schaue, AM Chen, R Chin… - JAMA, 2017 - jamanetwork.com
OBJECTIVES To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)–
variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker …